6526 related articles for article (PubMed ID: 3487622)
1. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
2. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
3. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.
Hersey P; Hasic E; MacDonald M; Edwards A; Spurling A; Coates AS; Milton GW; McCarthy WH
Br J Cancer; 1985 Jun; 51(6):815-26. PubMed ID: 3873953
[TBL] [Abstract][Full Text] [Related]
7. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
[TBL] [Abstract][Full Text] [Related]
8. Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma.
Hersey P; MacDonald M; Hall C; Spurling A; Edwards A; Coates A; McCarthy W
Cancer; 1986 Apr; 57(8 Suppl):1666-74. PubMed ID: 3485011
[TBL] [Abstract][Full Text] [Related]
9. Immunologic effects of interferon-alpha in man: treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis.
Peters M; Walling DM; Kelly K; Davis GL; Waggoner JG; Hoofnagle JH
J Immunol; 1986 Nov; 137(10):3147-52. PubMed ID: 3490513
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
12. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma.
Sakurai M; Iigo M; Ozaki A; Jett JR; Sasaki Y; Hoshi A; Saijo N
Jpn J Cancer Res; 1986 Aug; 77(8):774-81. PubMed ID: 3093426
[TBL] [Abstract][Full Text] [Related]
14. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
15. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
[TBL] [Abstract][Full Text] [Related]
16. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
17. Alteration of T cell subsets and induction of suppressor T cell activity in normal subjects after exposure to sunlight.
Hersey P; Haran G; Hasic E; Edwards A
J Immunol; 1983 Jul; 131(1):171-4. PubMed ID: 6223071
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
19. Interferon responsiveness of natural killer cells in type I human diabetes.
Negishi K; Gupta S; Chandy KG; Waldeck N; Kershnar A; Buckingham B; Charles MA
Diabetes Res; 1988 Jan; 7(1):49-52. PubMed ID: 3402165
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Treat Rev; 1985 Dec; 12 Suppl B():23-32. PubMed ID: 3833327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]